Lyell Immunopharma Inc.

0.46
0.02 (5.09%)
At close: Apr 22, 2025, 3:59 PM
0.44
-4.35%
After-hours: Apr 22, 2025, 06:58 PM EDT
5.09%
Bid 0.35
Market Cap 135.83M
Revenue (ttm) 61K
Net Income (ttm) -342.99M
EPS (ttm) -1.31
PE Ratio (ttm) -0.35
Forward PE -0.7
Analyst Hold
Ask 0.49
Volume 384,048
Avg. Volume (20D) 1,006,393
Open 0.46
Previous Close 0.44
Day's Range 0.43 - 0.47
52-Week Range 0.39 - 2.88
Beta -0.27

About LYEL

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2021
Employees 300
Stock Exchange NASDAQ
Ticker Symbol LYEL
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for LYEL stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 117.39% from the latest price.

Stock Forecasts
5 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The ... Unlock content with Pro Subscription
5 months ago
-5.22%
Lyell Immunopharma shares are trading higher after the company announced it will acquire privately-owned clinical-stage biotechnology company ImmPACT Bio.